Skip to main content
Premium Trial:

Request an Annual Quote

Mergers and Acquisitions in the RNAi Drugs Field, 2003 -- 2005

Premium
Mergers and Acquisitions in the RNAi Drugs Field, 2003 — 2005
Companies Deal Date Announced
SR Pharma and Atugen After shopping itself around, Atugen finds a buyer in UK-based SR Pharma. The deal gives SR Pharma a pipeline of RNAi drug candidates after it stopped development of another compound last year. June 21, 2005
Sirna Therapeutics and Skinetics Sirna bought Skinetics in order to pick up its RNAi technology for permanent hair removal. The deal cost Sirna about $2.4 million in stock, exclusive of milestones and royalties. Dec. 8, 2004
Benitec and Avocel Benitec acquired Avocel for $5.4 million in stock as part of its effort to establish a US base of operations. The deal also gave Benitec its first in-house drug development program: hepatitis C. May 17, 2004
Invitrogen and Sequitur Invitrogen bought Sequitur to acquire its Stealth RNAi technology and expand its line of RNAi research products. Sequitur had been developing the technology for therapeutic applications, but Invitrogen has stated that it remains focused on providing products for life science research and has no plans to expand into drug development. Nov. 4, 2003
Genta and Salus Therapeutics Genta acquired Salus for $13 million in stock, and up to an additional $17 million in stock or cash upon the achievement of certain milestones. The deal gave Genta access to RNAi technology, but the company has made little mention of its activities in this area since its failures with the antisense cancer drug Genasense. Aug. 14, 2003
Alnylam Pharmaceuticals and Ribopharma Alnylam acquired Germany-based Ribopharma in a deal that not only gave it ownership of the Kreutzer-Limmer IP portfolio, but also satisfied a key requirement of its licensing the Tuschl-1 and Tuschl-2 patent applications from the Max Planck Society. July 7, 2003
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.